Comprehensive analyses of phenylalanine hydroxylase variants and phenotypic characteristics of patients in the eastern region of Türkiye
Author:
Alavanda Ceren1ORCID, Ceylan Emine İpek12ORCID, Kılavuz Sebile34ORCID, Çıkı Kısmet4ORCID
Affiliation:
1. Department of Medical Genetics , Van Research and Training Hospital , Van , Türkiye 2. Department of Medical Genetics , Dr Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital , Ankara , Türkiye 3. Division of Child Nutrition and Metabolism, Department of Pediatrics, School of Medicine , Marmara University , İstanbul , Türkiye 4. Division of Child Nutrition and Metabolism, Department of Pediatrics , Van Research and Training Hospital , Van , Türkiye
Abstract
Abstract
Objectives
Phenylalanine hydroxylase (PAH) is predominantly a hepatic enzyme that catalyzes phenylalanine (Phe) into tyrosine, which is the rate-limiting step in Phe catabolism. Biallelic variants in the PAH gene cause PAH enzyme deficiency. Phenylketonuria (PKU) is an autosomal recessive disorder that causes neurologic, behavioral, and dermatological findings. PKU could be divided clinically into three types based on the blood Phe levels: classic phenylketonuria (cPKU), mild-moderate phenylketonuria (mPKU), and mild hyperphenylalaninemia (MHP). This study aimed to determine the phenotypic and genotypic characteristics of Turkish PKU patients in the eastern region of Türkiye.
Methods
Demographic characteristics, serum Phe levels, treatments, and PAH variants of 163 patients with PKU and hyperphenylalaninemia (HPA) were retrospectively evaluated. Blood Phe levels of the patients were analyzed with the high-performance liquid chromatography method. For PAH gene analysis, next-generation sequencing was performed.
Results
Of the 163 patients included in the study, 38 (23.3 %) had cPKU, 16 (9.8 %) had mPKU, and 109 (66.9 %) had MHP. Homozygous variants in the PAH gene were detected in 66 (40.5 %) of the patients, while compound heterozygous variants were detected in 97 (59.5 %) patients. Two novel and 35 recurrent variants in the PAH gene were detected. Of the two novel variants, one was missense (p.Phe351Leu) and the other was frameshift (p.Met276Cysfs*65). The most frequently detected variants were p.Thr380Met (18 %), p.Arg261Gln (16.8 %), and p.Ala300Ser (12.8 %). All patients with the homozygous c.1066-11G>A variant exhibited cPKU phenotype. The c.898G>T (p.Ala300Ser), c.1139C>T (p.Thr380Met), and c.1208C>T (p.Ala403Val) variants were statistically related to mild phenotype. On the other hand, c.592_613del (p.Tyr198Serfs*136), c.1028A>G (p.Tyr343Cys), and c.782G>A (p.Arg261Gln) variants were more frequently detected in the cPKU group.
Conclusions
Our study, conducted with patients from the eastern region of Türkiye, demonstrates the genetic heterogeneity in the Turkish population. Simultaneously, our research contributes to genotype–phenotype correlation and expands the genotypic spectrum by identifying novel variants.
Publisher
Walter de Gruyter GmbH
Reference28 articles.
1. Ozalp, I, Coşkun, T, Tokatli, A, Kalkanoğlu, HS, Dursun, A, Tokol, S, et al.. Newborn PKU screening in Turkey: at present and organization for future. Turk J Pediatr 2001;43:97–101. 2. Hillert, A, Anikster, Y, Belanger-Quintana, A, Burlina, A, Burton, BK, Carducci, C, et al.. The genetic landscape and epidemiology of phenylketonuria. Am J Hum Genet 2020;107:234–50. https://doi.org/10.1016/j.ajhg.2020.06.006. 3. Scriver, CR. The PAH gene, phenylketonuria, and a paradigm shift. Hum Mutat 2007;28:831–45. https://doi.org/10.1002/humu.20526. 4. Thöny, B, Auerbach, G, Blau, N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J 2000;347:1–16. https://doi.org/10.1042/bj3470001. 5. Thöny, B, Blau, N. Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum Mutat 2006;27:870–8. https://doi.org/10.1002/humu.20366.
|
|